Christian Grenier
Chief Executive Officer chez GENOWAY
Profil
Christian Grenier is the founder of Urogene SA, which was founded in 2009.
He held the title of Chairman from 2009 to 2012.
Currently, he is the Chairman & Chief Executive Officer at genOway SA and a Director at Delpharm SAS.
In the past, he was the Chairman-Supervisory Board at Neorphys SAS and WatchFrog SA. He also held the position of Principal at McKinsey & Co., Inc. and BioVision, Inc. Mr. Grenier received his undergraduate degree from INSEAD and ESCP Europe Campus Paris.
Postes actifs de Christian Grenier
Sociétés | Poste | Début |
---|---|---|
GENOWAY | Chief Executive Officer | - |
Delpharm SAS
Delpharm SAS Pharmaceuticals: MajorHealth Technology Delpharm SAS develops and manufactures drugs. The company is headquartered in Issy-les-Moulineaux, France. | Director/Board Member | - |
Anciens postes connus de Christian Grenier
Sociétés | Poste | Fin |
---|---|---|
Neorphys SAS
Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Chairman | 11/03/2014 |
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Founder | 17/10/2012 |
WatchFrog SA
WatchFrog SA Medical SpecialtiesHealth Technology Watchfrog SA creates and markets solutions for the in vivo detection of chemical, pharmaceutical and cosmetic substances. The firm offers to incorporate in vivo significance to early in vitro stage of drug discovery. It also offers biotechnological tools to accelerate environmental risk assessment. The company was founded by Barbara Demeneix and Gregory Lemkine in 2005 and is headquartered in Evry, France. | Chairman | - |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology BioVision, Inc. manufactures pharmaceutical products for apoptosis and cell signaling. It offers assay kits, antibodies, and recombinant proteins and enzymes. The company is headquartered in Milpitas, CA. | Corporate Officer/Principal | - |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Christian Grenier
INSEAD | Undergraduate Degree |
ESCP Europe Campus Paris | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
GENOWAY | Health Technology |
Entreprise privées | 6 |
---|---|
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology BioVision, Inc. manufactures pharmaceutical products for apoptosis and cell signaling. It offers assay kits, antibodies, and recombinant proteins and enzymes. The company is headquartered in Milpitas, CA. | Health Technology |
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
Neorphys SAS
Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Health Technology |
WatchFrog SA
WatchFrog SA Medical SpecialtiesHealth Technology Watchfrog SA creates and markets solutions for the in vivo detection of chemical, pharmaceutical and cosmetic substances. The firm offers to incorporate in vivo significance to early in vitro stage of drug discovery. It also offers biotechnological tools to accelerate environmental risk assessment. The company was founded by Barbara Demeneix and Gregory Lemkine in 2005 and is headquartered in Evry, France. | Health Technology |
Delpharm SAS
Delpharm SAS Pharmaceuticals: MajorHealth Technology Delpharm SAS develops and manufactures drugs. The company is headquartered in Issy-les-Moulineaux, France. | Health Technology |